of the RET proto-oncogene showed no abnormalities and haplotype analysis using microsatellite markers (D lOS 141 and ZNF22) excluded linkage to the RET proto-oncogene. SSCP analysis and genomic sequencing of the VHL gene showed a C--T transition at nucleotide 712 in exon 3 substituting an arginine for tryptophan at codon 238 (R238W) in all three affected relatives. Family 330 contained three affected sibs (figure). Analysis of the RET and VHL genes showed no abnormality and linkage analysis using microsatellite markers linked to RET (DlOS141 and ZNF22) and VHL (D3S1038) could not exclude linkage to either gene.
Discussion
The identification of germline VHL gene mutations in two of the three familial phaeochromocytoma kindreds studied has illustrated the benefits of molecular genetic testing. Although neither family A nor family 386 had clinical evidence ofVHL disease, the R238W mutation detected in family 386 has been detected previously in four families with VHL disease and is associated with a high risk of phaeochromocytoma and other VHL related tumours, including renal cell carcinoma. Hence the identification of VHL gene mutations not only allows presymptomatic diagnosis but also changes the management and follow up of a family. The early detection of VHL tumours by presymptomatic screening reduces morbidity and mortality and gene carriers require regular surveillance (including annual ophthalmological examinations and renal imaging). The V155L substitution identified in family A has not been detected previously, but is unlikely to represent a polymorphism as it segregates with the disease, produces a non-conservative amino acid change, and has not been identified on 300 normal VHL alleles (unpublished observations). The failure to detect VHL or RET mutations in family 330 may result from the insensitivity of the mutation detection techniques, or may indicate further loci for familial phaeochromocytoma susceptibility.
Interfamilial differences in the frequency of phaeochromocytoma are well recognised in VHL disease. Missense mutations, in particular those at codon 238, are associated with a much higher frequency of phaeochromocytoma than germline deletions or intragenic mutations which are predicted to cause a truncated protein product. " The absence of other features of VHL disease in family A may represent incomplete penetrance or mutation specific variations in phenotype. For example, most VHL gene mutations associated with phaeochromocytoma also predispose to other VHL complications including renal cell carcinoma. However, a single ancestral mutation in families of German origin is associated with a high incidence of phaeochromocytoma but a low incidence of renal carcinoma.'4 This raises the possibility that some VHL mutations might predispose to phaeochromocytoma but be associated with a low risk of other VHL related complications. Further studies of the molecular genetics of familial and early onset phaeochromocytoma patients for RET and VHL gene mutations will provide information on the genetic epidemiology of phaeochromocytoma and provide insights into the genotype-phenotype correlation in VHL disease.
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